Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics Limited announced that the U.S. FDA has granted Fast Track Designation for its novel imaging small molecule, RAD 101, which targets fatty acid synthase to improve diagnostic precision for brain metastases. This designation highlights the seriousness of recurrent brain metastases and the need for innovative products to differentiate between tumor recurrence and other conditions, potentially enhancing clinical decision-making for over 300,000 patients diagnosed annually in the U.S.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas with high unmet medical needs. The company is listed on ASX and NASDAQ and has a pipeline of distinct and highly differentiated platform technologies, including peptides, small molecules, and monoclonal antibodies for use in cancer diagnostics and therapeutics.
Average Trading Volume: 4,436,932
Technical Sentiment Signal: Sell
Current Market Cap: A$58.35M
For a thorough assessment of RAD stock, go to TipRanks’ Stock Analysis page.